Lisa Dawn Snook, PA-C | |
759 Susquehanna Trl, Watsontown, PA 17777-8109 | |
(570) 538-1240 | |
Not Available |
Full Name | Lisa Dawn Snook |
---|---|
Gender | Female |
Speciality | Physician Assistant |
Location | 759 Susquehanna Trl, Watsontown, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164932323 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2083A0300X | Preventive Medicine - Addiction Medicine | MA059550 (Pennsylvania) | Secondary |
363A00000X | Physician Assistant | MA059550 (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Lisa Dawn Snook, PA-C 759 Susquehanna Trl, Watsontown, PA 17777-8109 Ph: (570) 538-1240 | Lisa Dawn Snook, PA-C 759 Susquehanna Trl, Watsontown, PA 17777-8109 Ph: (570) 538-1240 |
News Archive
The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.
Limited healthy literacy is a major barrier blocking many people from achieving good cardiovascular health or benefiting from effective treatment for heart attacks, heart failure, strokes and other cardiovascular diseases, according to a scientific statement published in the American Heart Association's journal Circulation.
A new way of detecting liver disease decades before it can become fatal has been developed by a team of scientists at the University of Dundee and NHS Tayside.
At approximately 2:30 pm on Monday, January 25th "Penn Medicine Team One" - the first medical team from Penn Medicine to fly to Haiti to provide expert medical care - departed from the Philadelphia International Airport.
Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.
› Verified 5 days ago